Articles tagged "Co-stimulation"

2021 American Transplant Congress
TIGIT Agonism Improves Immunosuppression of Cd8 T Cells by Ctla-4ig in a Treg Dependent Manner
C. R. Hartigan, D. Liu, M. L. Ford
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Costimulation blockade therapeutics for immunosuppression in transplant are less toxic than calcineurin inhibitors offering improved graft longevity and patient quality of life, but belatacept-resistant…
2021 American Transplant Congress
Association of Belatacept Conversion on Patient and Allograft Survival in Kidney Transplant Recipients with Congestive Heart Failure
H. Mogallapalli
Department of Medicine, University of Wisconsin-Madison, Madison, WI
*Purpose: Calcineurin inhibitors (CNI) exert deleterious effect on cardiovascular risk in kidney transplant recipients (KTRs). Belatacept conversion may reduce CV risk in KTRs. We hypothesized…
2020 American Transplant Congress
Costimulatory Signal Impacts Car Treg Fate and Function in Transplantation
B. Lamarthée¹, A. Marchal¹, S. Charbonnier¹, T. Blein¹, K. Vogt², M. Titeux¹, N. Pallet³, M. Delville¹, E. Six¹, D. Anglicheau⁴, C. Legendre⁴, B. Sawitzki², J. Taupin⁵, M. Cavazzana¹, I. André¹, J. Zuber¹
¹Inserm U1163, Institut Imagine, Paris, France, ²Department of Immunology, Charité University Hospital, Berlin, Germany, ³Inserm U1147, Centre Universitaire des Saints Pères, Paris, France, ⁴Service de Transplantation Rénale Adulte, Assistance Publique–Hôpitaux de Paris, Hôpital Necker, Paris, France, ⁵Inserm U1160, Centre Hayem, Paris, France
*Purpose: Donor-specific regulatory T-cell (Treg) therapy has emerged as a potent strategy to promote immune tolerance in experimental transplantation. However, a major stumbling block in…
2020 American Transplant Congress
Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation
T. L. Shertel¹, M. A. Wynd¹, M. A. Pereiras¹, J. T. McKeen¹, Y. Y. Yushkov², B. R. Schleich³, S. E. Geatrakas², A. Patel², M. J. Goldstein²
¹Pharmacy, Hackensack University Medical Center, Hackensack, NJ, ²Organ Transplant, Hackensack University Medical Center, Hackensack, NJ, ³Patient Safety and Quality, Hackensack University Medical Center, Hackensack, NJ
*Purpose: Our center created an immunosuppression protocol using de novo belatacept (DNB) in the setting of lymphocyte depletion to increase the utilization of deceased donor…
2020 American Transplant Congress
Targeting the CD40/CD40L Axis in Sensitized Nonhuman Primate Allotransplantation
Z. W. Fitch, R. Schmitz, M. Manook, A. Y. Choi, J. Yoon, J. Kwun, S. J. Knechtle
Duke University, Durham, NC
*Purpose: Blockade of the CD28/B7 costimulation pathway has shown great promise as part of desensitization and maintenance immunosuppression regimens in our sensitized nonhuman primate model.…
2020 American Transplant Congress
Novel Treatment of Acute Antibody-Mediated Rejection in a Nonhuman Primate Model of Kidney Allotransplantation
R. Schmitz¹, Z. W. Fitch¹, A. Y. Choi¹, M. Manook¹, J. Yoon¹, J. D. Lambris², J. Kwun¹, S. J. Knechtle¹
¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience acute antibody mediated rejection (AMR) with limited treatment options. We tested a novel treatment strategy for…
2020 American Transplant Congress
Maintenance Belatacept Therapy is Associated with Increased Rates of Polyoma Viremia
D. Conti, E. Maciera, D. Pluckrose, M. Garner, D. Schuster, S. Patel
Albany Medical Center, Albany, NY
*Purpose: The introduction of belatacept costimulatory blockade therapy has added a novel and powerful agent to the immunosuppressive armamentarium utilized after renal transplantation. However, limited…
2020 American Transplant Congress
Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients: Rejection Risk, Prevention and Transcriptional Signature in Allograft
N. Murakami¹, G. Reid², A. Weins¹, B. Adam², M. Mengel², L. Riella¹
¹Brigham and Women's Hospital, Boston, MA, ²University of Alberta, Edmonton, AB, Canada
*Purpose: Immune checkpoint inhibitor (ICI) use has changed the landscape of cancer treatment. Several cases of acute rejection in use of ICI have been reported,…
2020 American Transplant Congress
Strong Engagement of CD137 Suppresses Graft-Versus-Host Disease Through Dendritic Cells
H. Cho¹, J. Lee², B. Kwon³, S. Park⁴, H. Park⁴, K. Yoo², K. Park², J. Kim³, S. Kang³
¹Ulsan University Hospital, Ulsan, Korea, Republic of, ²Nephrology, Ulsan University Hospital, Ulsan, Korea, Republic of, ³Biomedical Research Center, Ulsan University Hospital, Ulsan, Korea, Republic of, ⁴Surgery, Ulsan University Hospital, Ulsan, Korea, Republic of
*Purpose: We previously demonstrated that anti-CD137 agonist prevent acute graft-versus-host disease (GVHD) and chronic GVHD in the parent-into-unirradiated F1 acute or chronic GVHD model. Although…
2020 American Transplant Congress
Belatacept versus Tacrolimus Combined with Antithymocyte Globulin in Kidney Transplantation
J. Goldman¹, A. Mitrokhin², B. Trivedi¹, V. Vidyasagar¹, N. Vadivel¹, N. Goes³, M. Hart¹
¹Swedish Medical Center, Seattle, WA, ²SUNY, Brooklyn, NY, ³Permanente Medical Group, Oakland, CA
*Purpose: Belatacept (BELA) used for maintenance immunosuppression (IS) after kidney transplant (KT) shows similar graft and patient survival, but improved allograft function, despite more rejection…

« Previous Page
1
…
4
5
6
7
8
…
30
Next Page »